About InterAx Biotech
InterAx Biotech is a company based in Villigen (Switzerland) founded in 2016. InterAx Biotech has raised $3.19 million across 7 funding rounds from investors including European Union, Verve Ventures and Investiere. InterAx Biotech offers products and services including Drug Discovery Platform and Lead Molecule Generation. InterAx Biotech operates in a competitive market with competitors including Slingshot Bioscience, Magnitude Biosciences, StemoniX, Signal Pharmaceuticals and Sequence Bio, among others.
- Headquarter Villigen, Switzerland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Interax Biotech Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.19 M (USD)
in 7 rounds
-
Latest Funding Round
$343.2 K (USD), Grant
Feb 01, 2020
-
Investors
European Union
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InterAx Biotech
InterAx Biotech offers a comprehensive portfolio of products and services, including Drug Discovery Platform and Lead Molecule Generation.
AI and modeling tool for creating high-efficacy drug leads
Process using experimental methods for safe drug candidates
People of InterAx Biotech
Unlock access to complete
Unlock access to complete
Funding Insights of InterAx Biotech
InterAx Biotech has successfully raised a total of $3.19M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $343.2 thousand completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in InterAx Biotech
InterAx Biotech has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Verve Ventures and Investiere.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on science and tech-driven startups
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked |
Investor details for InterAx Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InterAx Biotech
Investment portfolio details for InterAx Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - InterAx Biotech
Detailed financials for InterAx Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Interax Biotech Comparisons
Peer comparison for InterAx Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InterAx Biotech
InterAx Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Slingshot Bioscience, Magnitude Biosciences, StemoniX, Signal Pharmaceuticals and Sequence Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Next-generation synthetic cells are developed for diagnostics and therapeutics.
|
|
| Locked | Locked | Locked |
Cell-free in vitro assays are supplied to drug discovery firms.
|
|
| Locked | Locked | Locked |
Developing a commercial scale printer for the high-volume growth and differentiation of stem cells and stem cell products.
|
|
| Locked | Locked | Locked |
Small molecule drugs regulating disease-associated genes are developed.
|
|
| Locked | Locked | Locked |
Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases and develop medicines.
|
Detailed competitors of InterAx Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Interax Biotech
Complete news archive for InterAx Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InterAx Biotech
InterAx Biotech was founded in 2016.
InterAx Biotech is headquartered in Villigen, Switzerland. It is registered at Villigen, Aargau, Switzerland.
InterAx Biotech is a funded company, having raised a total of $3.19M across 7 funding rounds to date.
InterAx Biotech is a spin-off from ETH Zurich that uses mutated arrestins as novel biosensors and has a computational platform for analysis. They have a combination of proprietary arrestin-based biosensors and computational methods which allow for quantitative comparison of drug-induced GPCR signalling pathways. This helps the identification of not just the GPCR reaction with the drug, but also if the reaction is beneficial or adverse. The company develops and sells drug screening packages which help in selecting drug candidates, quantifying cellular responses and in predicting drug action. The company offers two main product lines of Arrestin mutants (with biosensor applications) for in-vitro assays and cellular assays. The company also offers image analysis services mainly for fluorescence microscopy images which help in detecting, delineating and quantifying subcellular structures. The company is supported by the Paul Scherer Institute and a finalist of the Swiss Innovation Challenge.
InterAx Biotech's top competitors include Magnitude Biosciences, Slingshot Bioscience and StemoniX.
InterAx Biotech offers Drug Discovery Platform and Lead Molecule Generation.
InterAx Biotech has 6 investors. Key investors include European Union, Verve Ventures, Investiere, Falcon III Ventures, and EIC Fund.